New monoclonal antibodies in renal transplantation

Minerva Urologica e Nefrologica

Volumn 55, Issue 1, 2003, Pages 57-66

  Vincenti, F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antibodies, monoclonal; Kidney transplantation; Receptor fusion proteins

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; B7 ANTIGEN; CD86 ANTIGEN; CORTICOSTEROID; CYCLOSPORIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACLIZUMAB; EFALIZUMAB; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; RITUXIMAB; TACROLIMUS;

DRUG EFFECT; DRUG MONITORING; EFFECTOR CELL; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOGENICITY; KIDNEY ALLOGRAFT; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MAINTENANCE THERAPY; RECEPTOR BLOCKING; RECIPIENT; REVIEW;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD3; ANTIGENS, CD45; ANTIGENS, NEOPLASM; GLYCOPROTEINS; HUMANS; IMMUNOSUPPRESSION; KIDNEY TRANSPLANTATION; RECEPTORS, INTERLEUKIN-2;

EID: 0037773336     PISSN: 03932249     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Ortho Multicenter Study Group: a randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med 1985;313:337-42.
2. Abramowicz D, Sehandere L, Goldman M. Release of tumor necrosis factor, interleukin-2, and γ-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation 1989;47:606-8.
3. Vincenti F, Vasconcelos M, Birnbaum J, Tomlanovich SJ, Amend WJC, Melzer JS et al. Pentoxifylline reduces the first dose reactions following OKT3. Transplant Proc 1993;25 Suppl 1:57-9.
4. Vincenti F, Kirkman R, Light S, Bumgardner G, Pescovitz M, Halloran P et al. Interleukin 2 receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Eng J Med 1998;338:161-5.
5. Kahan BD, Rajagopalan PR, Hall M. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. Transplantation 1999;67:276-84.
6. Vieira CA, Agarwal A, Book BK, Sidner RA, Zeni T, Gebel HM et al. Rituxan for reduction of anti-HLA antibodies in patients awaiting renal transplantation (abstract #870). Am J Transpl 2002;2Suppl3:356.
7. Sollinger HW, Becker Y, Pirch J. The use of rituxan in transplantation. Am J Transplant 2001;1:A489.
8. Kutukculer N, Shenton BK, Clark K, Riggs KM, Forsythe JL, Kirby JA et al. Renal allograft rejection: the temporal relationship and predictive value of plasma TNF (α and β), IFN-γ and soluble ICAM-1. Transpl Int 1995;8:45-50.
9. Azzawi M, Hasleton PS, Hutchinson IV. TNF-α in acute cardiac transplant rejection. Cytokines Cell Mol Ther 1999;5:41-9.
10. McLaughlin PJ, Aikawa A, Davies HM, Ward RG, Bakran S, Sells RA et al. Evaluation of sequential plasma and urinary tumor necrosis factor α levels in renal allograft recipients. Transplantation 1991;51:1225-9.
11. Imagawa DK, Millis JM, Olthoff KM, Derus LJ, Chia D, Sugich LR et al. The role of tumor necrosis factor in allograft rejection. 1. Evidence that elevated levels of tumor necrosis factor-α predict rejection following orthotopic liver transplantation. Transplantation 1990;50:219-25.
12. Depper JM, Leonard WJ, Robb RJ, Waldmann TA, Greene WC. Blockade of the interleukin-2 receptor by anti Tac antibody: inhibition of human lymphocyte activation. J Immunol 1983;131:690-6.
13. Waldmann TA, Goldman CK. The multichain interleukin-2 receptor: a target for immunotherapy of patients receiving allografts. Am J Kidney Dis 1989;14:45-53.
14. Bumgardner GL, Amend WC, Ascher NL, Vincenti F. Single-center long-term results of renal transplantation for IgA nephropathy. Transplantation 1998;65:1053-60.
15. Vincenti F, Bumgardner GL, Gaston RS, Kirkman RL, Light S, Patel IH et al. Addition of daclizumab to mycophenolate mofetil, cyclosporine, and steroids in renal transplantation: pharmacokinetics, safety, and efficacy. Submitted, 2002.
16. Lawen J, Davies E, Mourad G, Oppenheimer F, Gonzalez-Molina M, Bourbigot B et al. Basiliximab (Simulect®) is safe and effective in combination with triple therapy of Neoral®, steroids and Cellcept® in renal transplant recipients [abstract]. Transplantation 2000;69:S260.
17. Ciancio G, Burke GW, Suzart K, Roth D, Kupin W, Rosen et al. Transplantation Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients. Transplantation 2002;15:1100-6.
18. Deierhoi M, Hudson SL et al. Clinical experience with a 2 dose regimen of daclizumab in cadaveric renal transplantation [abstract]. Transplantation 2000;69:S260.
19. Vincenti F, Pace D, Birnbaum J, Lantz M. Pharmacokinetic and pharmacodynamic studies of one or two doses of daclizumab in renal transplantation. Am J Transpl 2002; (In press).
20. Sarwal MM, Yorgin PD, Alexander S, Millan MT, Belson A, Belander N et al. Promising early outcomes with a novel, complete steroid avoidance immunosuppression protocol in pediatric renal transplantation. Transplantation 2001;72:13-21.
21. Vincenti F, Monaco A, Grinyo J, Kinkhabwala M, Roza A et al. Rapid steroid withdrawal versus standard steroid therapy in patients treated with basilixamab, cyclosporine, and mycophenolate mofetil for the prevention of acute rejection in renal transplantation. Transplant Proc 2001;33:1011-2.
22. Cole E, Landsberg D, Russell D, Zaltzman J, Kiberd B, Caravaggio C et al. A pilot study of steroid-free immunosuppression in the prevention of acute rejection in renal allograft recipients. Transplantation 2001;72:845-50.
23. Vincenti F, Ramos E, Brattstrom C, Cho S, Ekberg H, Grinyo J et al. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation 2001;71:1282-7.
24. Vincenti F. Interleukin-2 receptor monoclonal antibodies in renal transplantation: current use and emerging regimens. Transplant Proc 2001;33:3169-7.
25. Flechner SM, Cook DJ, Goldfarb D, Modlin C, Mastroianni B, Savas K et al. A randomized trial of sirolimus vs cyclosporine in kidney transplantation: impact on blood cells, lymphocyte subsets, and flow crossmatches [abstract]. Am J Transplant 2002;2:470.
26. Larson TS, Velosa JA, Prieto M, Lund WJ, Griffin MD, Gloor JM et al. Kidney transplantation without calcineurin-inhibitors: a randomized trial of sirolimus vs tacrolimus [abstract]. Am J Transplat 2002;2:237.
27. γ1 (Ala-Ala) in the treatment of acute renal allograft rejection. Transplantation 1999;68:608-16.
28. Friend PJ, Hale G, Chatenoud L, Rebello P, Bradley J, Thiru S et al. Phase I study of an engineered aglycosylated humanized CD3 antibody in renal transplant rejection. Transplantation 1999;68:1632-7.
29. Norman DJ, Vincenti F, de Mattos AM, Barry JM, Levitt DJ, Wedel NI et al. Phase I trial of HuM291, a humanized anti-CD3 antibody, in patients receiving renal allografts from living donors. Transplantation 2000;70:1707-12.
30. Kaplan B, Norman D, Curtis J, Matas A, Levitt D, Light S. A phase I/II dose escalation study of the humanized anti CD3 antibody HuM291 [abstract]. Transplantation 2000;S261.
31. Sayegh MH, Turka LA. The role of T-cell costimulatory activation pathways in transplant rejection. N Engl J Med 1998;448:1813-21.
32. Kirk AD, Knechtle SJ, Sollinger HW, Vincenti FG, Stecher S, Nadeau K. Preliminary results of the use of humanized anti-CD154 in human renal allotransplantation. Am J Transplant 2001;1 Suppl 1:190.
33. Kirk AD, Burkly LC, Batty DS, Baumgartner RE, Benning JD, Buchanan K et al. Tretment with humanized monoclonal antibody against CD 154 prevents acute renal alografts rejection in nonhman primates. Nat Med 1999;5:686-93.
34. Kirk AD, Tadaki DK, Celniker A, Batty DS, Berning JD, Colonna JO et al. Induction therapy with monoclonal antibodies specific for CD80 and CD86 delays the onset of acute renal allograft rejection in non-human primates. Transplantation 2001;72:377-84.
35. Ossevoort MA, Ringers J, Kuhn E-M, Boon L, Lorré K, Van den Hout Y et al. Prevention of renal allograft rejection in primates by blocking the B7/CD28 pathway. Transplantation 1999;68:1010-8.
36. Vincenti FV. What's in the pipeline. New immunosuppressive drugs in transplantation. Am J Transplant 2002;2:898-903.
37. Koulova L, Clark EA, Shu G, Dupont B. The CD28 ligand B7/BB1 provides costimulatory signals for alloactivation of CD4+ T cells. J Exp Med 1991;173:721-30.
38. Tan P, Anasetti C, Hansen JA, Melrose J, Brunvand M, Bradshaw J et al. Induction of allantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1. J Exp Med 1993;177:165-73.
39. Linsley PS, Greene JL, Brady W, Bajorath J, Ledbetter JA, Peach R. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity 1994;1793-801.
40. Arnaout MA. Structure and function of the leukocyte adhesion molecules CD11/CD18. Blood 1990;75:1037-50.
41. Nakakura EK, Shorthouse RA, Zheng B, McCabe SM, Jardieu PM, Morris RE. Long-term survival of solid organ allografts by brief anti-lymphocyte function-associated antigen-1 monoclonal antibody monotherapy. Transplantation 1996;62:547-52.
42. Salmela K, Wramner L, Ekberg H, Hauser I, Bentdal Ø, Lins LE et al. A randomized multicenter trial of the anti-ICAM-1 monoclonal antibody (enlimomab) for the prevention of acute rejection and delayed onset of graft function in cadaveric renal transplantation. Transplantation 1999;67:729-36.
43. Vincenti F, Mendez R, Rajagopalan PR, Wilkinson A, Butt K, Laskow D et al. A phase I/II trial of anti-CD11a monoclonal antibody in renal transplantation. Am J Transplant 2001;1 Suppl 1:276.
44. Thomas ML. The leukocyte common antigen family. Ann Rev Immunol 1989;7:339-69.
45. Basadonna G, Auersvald L, Khuong C, Zheng X, Kashio N, Zekzer D et al. Antibody mediated targeting of CD45 isoforms: a novel immunotherapeutic strategy. Proc Natl Acad Sci USA, 1998;95:3821-6.
46. Lazarovits A, Poppema S, Zhang Z, Khandaker K, LeFeuvre C, Singhal S et al. Prevention and reversal of renal allograft rejection by antibody against CD45RB. Nature 1996;380:717-20.
47. Rothstein DM, Basadonna GP. Anti-CD45: a new approach towards tolerance induction. Graft 1999;2:239-45.
48. Calne R, Moffatt SD, Friend PJ, Jamieson NV, Bradley JA, Gale G et al. Campath 1H allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients. Transplantation 1999;68:1613-6.
49. Kirk AD, Hale DA, Hoffmann SC, Kampen RL, Kleiner DE, Mannon RB et al. Results from a human tolerance trial using campath-1H with and without infliximab. Am J Transplant 2002;2 Suppl 3:378.
50. Knechtle SJ, Pirsch JD, Becker BN, Odorico JS, D'Allessandro AM, Chin LT et al. Campath-1H induction plus rapamycin monotherapy in renal transplantation. Am J Transplant 2002;2 Suppl 3:459.